Excipients without the active substance clinical trials

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-1) WITH AN OPEN-LABEL EXTENSION

This study is looking into a new medication called PLS240 for people with advanced kidney disease on dialysis. It aims to see if PLS240 can help manage a common kidney-related hormone problem called secondary hyperparathyroidism, and to check if it's safe to use.